NCT06379217
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06379217
Title NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Recruitment Active, not recruiting
Gender male
Phase Phase I
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | GBR | FRA | ESP | DEU

Facility Status City State Zip Country Details
Nebraska Cancer Specialists Omaha Nebraska 68130 United States Details
Memorial Sloan Kettering Cancer Ctr New York New York 10017 United States Details
Novartis Investigative Site Nantes 44093 France Details
Novartis Investigative Site München 80377 Germany Details
Novartis Investigative Site Rostock 18057 Germany Details
Novartis Investigative Site L'Hospitalet de Llobregat Barcelona 08907 Spain Details
Novartis Investigative Site Madrid 28041 Spain Details
Novartis Investigative Site Sutton Surrey SM2 5PT United Kingdom Details
Novartis Investigative Site London NW3 2QG United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field